What is Cell > Point?
Cell > Point operates at the intersection of molecular diagnostics and therapeutic intervention, specializing in the development of universal imaging compounds. By leveraging exclusive licenses from The University of Texas MD Anderson Cancer Center, the company has built a robust intellectual property portfolio, including 59 issued patents for its Oncardia platform. Its core competency lies in the creation of one-vial kits that streamline the staging and treatment monitoring of cancer and ischemic diseases, positioning the firm as a critical player in the precision medicine landscape. The company's focus on universal molecular imaging compounds provides a scalable framework for addressing unmet needs in high-acuity medical conditions.
How much funding has Cell > Point raised?
Cell > Point has raised a total of $226K across 2 funding rounds:
Debt
$150K
Debt
$76K
Debt (2020): $150K with participation from PPP
Debt (2021): $76K led by PPP
Key Investors in Cell > Point
PPP
Public-Private Partnership
What's next for Cell > Point?
With the recent influx of capital, Cell > Point is well-positioned to accelerate its clinical development programs and expand its manufacturing footprint. The strategic roadmap likely involves transitioning its lead assets through final regulatory hurdles and optimizing the supply chain for its one-vial diagnostic kits. As the company moves deeper into its late-stage lifecycle, the focus will shift toward market penetration and the potential for strategic partnerships with global healthcare providers. Continued investment in its organic formulation pipeline will be essential to maintaining its competitive edge in the rapidly evolving field of molecular therapeutics and diagnostic imaging.
See full Cell > Point company page
